INTEGRATIVE & ALTERNATIVE ONCOLOGY • ADVANCED CANCER CARE
Stage 4 Cancer Treatment: Integrative Care for Metastatic Cancer
Advanced Cancer Does Not Mean We Stop Looking for Options
Individualized physician-directed cancer care for metastatic, recurrent and heavily treated cancers.
A Stage 4 cancer diagnosis changes the conversation—but it does not mean there is only one path forward. At Sunridge Medical, we review the cancer, where it has spread, previous treatments, biomarker information, the patient’s current health and the goals that matter now.
Patients come to us during treatment, after progression, at recurrence, when standard options have become limited, or when they want to explore a broader physician-directed strategy.
STAGE 4 CANCER • KEY POINTS
Stage 4 Cancer Treatment: Quick Answers
UNDERSTANDING THE DIAGNOSIS
What Does Stage 4 Cancer Mean?
For many solid tumors, Stage 4 means cancer has spread beyond the primary tumor and regional area to one or more distant sites. This spread is called metastasis. The metastatic tumor is still named for the cancer where it began. Breast cancer that spreads to the liver remains metastatic breast cancer; colon cancer that spreads to the lung remains metastatic colorectal cancer.1
Metastasis is a multistep biological process. Cancer cells invade nearby tissue, enter lymphatic channels or blood vessels, travel through the circulation, survive at a distant site and then establish a new tumor environment. Because each cancer type has different biology, the pattern of spread and the treatments that matter most can vary substantially.
Stage 4 Cancer vs. Metastatic Cancer
For many common solid cancers, the terms are used interchangeably. There are important exceptions. Some cancers use different staging systems, and Stage 4 in lymphoma or leukemia does not mean exactly the same thing as metastatic Stage 4 breast, lung or colon cancer.
Stage 4 Cancer vs. Advanced Cancer
Advanced cancer is a broader term. It may refer to metastatic disease, very locally advanced disease, recurrent disease or cancer that is difficult to control. A patient can have advanced cancer without every situation fitting a simple “Stage 4” label.
Stage 4 Cancer vs. Terminal or End-Stage Cancer
These terms should not be treated as synonyms. Stage 4 describes the extent of cancer. Terminal or end-stage cancer describes a clinical situation in which the disease can no longer be controlled and life expectancy is limited. NCI specifically distinguishes advanced or metastatic disease from end-stage disease and emphasizes that goals of care can change over time.8
TREATMENT GOALS
What Are the Goals of Stage 4 Cancer Treatment?
The goals are individualized. Depending on the cancer and the patient, the plan may aim to:
- shrink measurable tumors;
- slow or stop progression;
- produce a partial or complete response;
- control cancer for as long as possible;
- treat a dangerous or symptomatic metastatic site;
- reduce pain, shortness of breath, obstruction or neurologic symptoms;
- preserve organ function;
- improve treatment tolerance;
- maintain strength, nutrition and activity;
- protect quality of life;
- create time for additional treatment options or clinical trials to become available.
For one patient, the most important goal may be maximal tumor response. For another, the goal may be disease control with fewer side effects. Serious Stage 4 metastatic cancer treatment starts by defining what is medically realistic and what matters most to the person receiving care.
CASE REVIEW
A Stage 4 Cancer Case Deserves a Complete Re-Review
When cancer has metastasized or progressed after previous treatment, the answer is rarely as simple as choosing “another drug.” The most useful question is: What does the entire case tell us now?
1. Confirm the Diagnosis and Current Disease Pattern
Review pathology, imaging, operative reports and the timeline of progression. If the cancer has changed behavior, a repeat biopsy may sometimes be appropriate because metastatic tumors can evolve under treatment pressure.
2. Review Every Previous Treatment and Response
Which treatments produced a response? How long did the response last? What toxicities occurred? Did progression happen during treatment or after it was stopped? Treatment history can reveal sensitivity, resistance and therapies that should not simply be repeated.
3. Revisit Biomarker and Molecular Testing
Biomarker testing looks for genes, proteins and other tumor features that may help select therapy. NCI notes that even patients with the same cancer type can have different biomarkers and that testing can help guide treatment choice.2
4. Look for Tissue-Agnostic Opportunities
Some modern cancer drugs are approved because of a molecular feature rather than the organ where the cancer began. NCI’s tumor-agnostic therapy resource describes the growing use of next-generation sequencing to identify genetic or immune markers that can match a patient to targeted or immune therapy.5
5. Reassess the Metastatic Sites Themselves
Bone, brain, liver, lung and peritoneal metastases can create very different risks. A lesion threatening the spinal cord, airway, bile duct, bowel or a weight-bearing bone may require a local intervention even when the overall disease is being treated systemically.
6. Evaluate the Patient, Not Only the Tumor
Kidney and liver function, blood counts, weight loss, nutrition, pain, neuropathy, performance status, sleep, inflammation, hydration, medications and treatment tolerance all influence what can safely and realistically be done next.
PRECISION ONCOLOGY
Biomarker Testing and Precision Oncology in Stage 4 Cancer
Precision oncology is especially important in metastatic disease because modern treatment can depend on the molecular vulnerabilities of the tumor. Biomarker testing may use tumor tissue, blood-based testing in selected situations, or both. The purpose is not to order the largest possible panel for every patient; it is to identify information that can change treatment.
Depending on cancer type, relevant findings may include DNA mutations, gene fusions, amplifications, hormone receptors, HER2 status, mismatch-repair deficiency, microsatellite instability, tumor mutational burden and other cancer-specific biomarkers. The list changes rapidly as new treatments are approved, which is why current interpretation matters.2, 3, 5
NCI maintains a continuously updated list of targeted therapies approved for specific cancer types and solid tumors with selected biomarkers.3
SYSTEMIC • LOCAL • CLINICAL TRIAL OPTIONS
Stage 4 Cancer Treatment Options
There is no universal Stage 4 cancer protocol. Treatment is built around the primary cancer, molecular subtype, metastatic sites, treatment history and the patient’s health.
Chemotherapy
Chemotherapy remains an important systemic treatment for many metastatic cancers. It may be used alone or combined with targeted therapy, immunotherapy, radiation or other agents. The drug combination and sequence are cancer-specific.
Immunotherapy
Immune checkpoint inhibitors and other immunotherapies can produce meaningful and sometimes durable responses in selected cancers. NCI lists checkpoint inhibitors as approved for multiple tumor types, including cancers of the lung, kidney, liver, bladder, breast, colon, rectum, head and neck, melanoma and others.4
Targeted Therapy
Targeted therapy acts on specific molecular changes or pathways that cancer cells depend on. These therapies have transformed treatment for selected patients with metastatic lung, breast, colorectal, kidney, thyroid, melanoma and many other cancers.3
Hormone Therapy
Hormone-sensitive breast and prostate cancers can often remain responsive to endocrine or androgen-directed treatment even after metastasis. Modern combination regimens may be substantially different from older single-agent approaches.
Antibody-Drug Conjugates and Monoclonal Antibodies
Modern antibody therapies can deliver targeted treatment, block growth signals or help the immune system recognize cancer. Many are now standard treatments for selected metastatic cancers.
Radiation Therapy
Radiation can be used for painful bone metastases, brain metastases, spinal disease, bleeding, obstruction and other local problems. Highly focused techniques such as stereotactic body radiation therapy (SBRT/SABR) are also used in selected metastatic settings.
Surgery, Ablation and Other Local Treatments
Stage 4 cancer is usually treated systemically, but selected patients may still benefit from surgery, ablation, embolization or other local treatment—particularly when metastatic disease is limited, a lesion is causing a dangerous complication, or local control is expected to improve the treatment strategy.
Radiopharmaceuticals and Molecularly Targeted Radiation
Some cancers can be treated with radioactive compounds designed to target specific tumor features. This field continues to expand, particularly in prostate and neuroendocrine cancers.
Clinical Trials
Clinical trials can be especially important after standard treatments have been exhausted or when a biomarker matches an investigational therapy. Eligibility depends on the cancer type, molecular profile, previous treatments, organ function and other clinical factors.
LIMITED METASTATIC DISEASE
What Is Oligometastatic Cancer?
Oligometastatic cancer refers to metastatic disease with a limited number of metastatic sites. The concept matters because a small subgroup of patients may benefit from aggressively treating visible metastases in addition to systemic therapy.
The randomized SABR-COMET phase II trial studied patients with a controlled primary tumor and one to five metastatic lesions. Long-term follow-up found a higher five-year overall-survival rate in the group receiving stereotactic ablative radiotherapy, although the original trial also reported important treatment-related toxicity and the findings do not apply to every patient with metastatic cancer.6, 7
This is why a Stage 4 diagnosis should not automatically end discussion of local therapy. The number, location and biology of metastases matter.
PROGRESSION AFTER TREATMENT
What If Chemotherapy Has Stopped Working?
This is one of the most common reasons patients seek a new Stage 4 cancer treatment review.
Progression after chemotherapy does not necessarily mean that every meaningful option has been exhausted. The next review may include:
- confirming true progression on current imaging;
- reviewing whether the disease progressed everywhere or only at one or two sites;
- re-biopsy or updated molecular testing when appropriate;
- checking whether a new targeted therapy or immunotherapy is available;
- reviewing unused approved treatment lines;
- considering metastasis-directed radiation or other local treatment;
- searching for clinical trials;
- addressing treatment-related weakness, weight loss, pain or organ dysfunction that may be limiting the ability to continue therapy;
- considering a physician-directed integrative strategy alongside or around the active oncology plan.
WHEN STANDARD OPTIONS ARE LIMITED
What If You Have Been Told There Are No More Treatment Options?
Sometimes “no more options” means no more standard treatment is expected to provide enough benefit to justify its toxicity. Sometimes it means the patient is too medically fragile for additional conventional therapy. Sometimes it means all usual treatment lines have been used.
Those are different situations and deserve different conversations.
A careful re-review can ask:
- Is the pathology still correct and complete?
- Has comprehensive biomarker testing been performed?
- Are there tumor-agnostic therapies that match the molecular findings?
- Are there current clinical trials?
- Is there an oligometastatic or symptomatic site that could be treated locally?
- Is poor performance status partly reversible—for example from dehydration, anemia, infection, malnutrition, pain or medication effects?
- What treatments could improve symptoms or quality of life even if the disease cannot be eradicated?
- What does the patient actually want from the next phase of care?
There are also times when additional anti-cancer treatment is unlikely to help. In those situations, high-quality palliative care remains active medical care. ASCO’s 2024 guideline recommends early specialist palliative care for patients with advanced solid tumors and hematologic malignancies, particularly when symptoms or quality-of-life concerns are present.9
PHYSICIAN-DIRECTED INTEGRATIVE ONCOLOGY
Integrative and Alternative Treatment for Stage 4 Cancer
Patients searching for alternative treatment for Stage 4 cancer are often looking for more than another drug. They may want to explore tumor biology from a different angle, improve treatment tolerance, rebuild strength, address nutrition and metabolism, reduce symptom burden, support sleep and function, or consider natural compounds with cancer research behind them.
At Sunridge Medical, integrative care is physician-directed and individualized. The role of a therapy depends on its evidence, biological rationale, interaction profile, the patient’s condition and the current oncology plan.
High-Dose IV Vitamin C
Pharmacologic IV vitamin C has a substantial mechanistic literature and growing human clinical research. A 2024 randomized metastatic pancreatic cancer trial reported longer median overall and progression-free survival when pharmacologic IV ascorbate was added to gemcitabine/nab-paclitaxel, without detected worsening of overall toxicity or quality of life. The study was relatively small and should be replicated, but it represents one of the strongest randomized signals in modern integrative oncology.12
Read the complete Sunridge review of IV vitamin C and cancer →
Mistletoe Extract
European mistletoe extracts have been studied extensively in supportive and integrative oncology, particularly for quality-of-life outcomes, treatment tolerance and immune effects. Formulation, route, dose and clinical context matter.
Curcumin
Curcumin has been studied across inflammatory, signaling, apoptotic and metabolic pathways in cancer models, with limited but growing human oncology data. Bioavailability and formulation are major considerations.
Alpha Lipoic Acid
Alpha lipoic acid has research involving mitochondrial metabolism, redox signaling and supportive oncology. Human anti-cancer evidence remains much smaller than the preclinical literature, and treatment interactions can matter.
Artemisinin
Artemisinin derivatives have attracted oncology research interest because of iron-dependent and redox-related mechanisms. Evidence varies substantially by cancer type and formulation.
Ozone Autohemotherapy
Major ozone autohemotherapy is used in some integrative medical settings for redox and circulatory effects. Its role in cancer care should be understood as an adjunctive physician-directed therapy rather than a proven stand-alone treatment for metastatic cancer.
Nutrition, Metabolic Health and Treatment Tolerance
Stage 4 cancer can create major nutritional and metabolic challenges. Loss of appetite, sarcopenia, cachexia, blood-sugar disruption, gastrointestinal problems, dehydration and treatment toxicity can directly affect strength and the ability to continue treatment. Nutrition support should be practical, individualized and compatible with the oncology plan.
BONE • BRAIN • LIVER • LUNG • PERITONEUM
Stage 4 Cancer by Site of Metastasis
The location of metastatic disease can influence both symptoms and treatment priorities. NCI identifies bone, liver and lung among the most common metastatic sites across many solid tumors.1
Bone Metastases
Bone metastases can cause pain, fracture risk, high calcium levels and spinal-cord compression. Treatment may include systemic therapy, bone-strengthening medication, radiation, surgery or stabilization, depending on the location and risk.
Brain Metastases
Brain metastases may cause headaches, weakness, seizures, speech or visual changes, dizziness or cognitive symptoms. Treatment can involve steroids for swelling, stereotactic radiosurgery, surgery, whole-brain radiation in selected situations, and systemic treatments that have activity in the brain.
Liver Metastases
Liver metastases can affect liver function, appetite, energy and abdominal comfort. In addition to systemic treatment, selected patients may be evaluated for surgery, ablation, embolization or radiation-based approaches depending on cancer type and disease distribution.
Lung Metastases
Lung metastases may be asymptomatic or may cause cough, chest symptoms or shortness of breath. Some patients with limited lung metastases can be considered for surgery, SBRT or ablation in addition to systemic treatment.
Peritoneal Metastases
Peritoneal spread can occur with colorectal, ovarian, pancreatic, gastric and other cancers. Symptoms may include abdominal swelling, bowel problems, pain and ascites. Management depends heavily on the primary cancer and extent of disease.
CANCER-SPECIFIC TREATMENT
Stage 4 Cancer Is Different for Every Primary Cancer
Searches for “Stage 4 cancer” can be misleading because metastatic breast cancer, metastatic lung cancer, metastatic colorectal cancer and metastatic prostate cancer can have entirely different biology, therapies and outlooks.
- Metastatic breast cancer: treatment may be driven by hormone-receptor status, HER2 expression, germline mutations and previous therapies.
- Stage 4 lung cancer: molecular testing and PD-L1 status can radically change first-line treatment; selected tumors have highly effective targeted therapies.
- Metastatic colorectal cancer: RAS, BRAF, HER2, mismatch-repair status and tumor sidedness can influence therapy.
- Metastatic prostate cancer: hormone-sensitive and castration-resistant disease have different treatment strategies, and combination treatment is increasingly important.
- Metastatic melanoma: immune checkpoint therapy and BRAF/MEK-targeted therapy can be central when appropriate.
- Metastatic kidney cancer: immunotherapy and targeted combinations have transformed treatment.
- Stage 4 pancreatic cancer: chemotherapy remains central, while molecular findings may identify targeted or clinical-trial opportunities in selected patients.
PROGNOSIS & LIFE EXPECTANCY
Stage 4 Cancer Life Expectancy: Why a Single Number Is Often Misleading
Stage 4 cancer life expectancy is one of the most common searches after diagnosis—and one of the easiest topics to oversimplify.
There is no single life-expectancy number for Stage 4 cancer. Prognosis can be influenced by:
- the primary cancer type;
- molecular subtype and biomarkers;
- where the cancer has spread;
- number and volume of metastatic sites;
- whether the disease is newly metastatic or heavily pretreated;
- how well the cancer responds to treatment;
- availability of targeted therapy or immunotherapy;
- overall health and performance status;
- weight loss and nutritional status;
- organ function;
- treatment complications;
- access to later-line therapies and clinical trials.
NCI notes that some people live for years with metastatic cancer that is well controlled.1 Population survival statistics describe groups of patients treated in the past; they cannot precisely predict what will happen to an individual patient today.
RESPONSE • REMISSION • LONG-TERM CONTROL
Can Stage 4 Cancer Go Into Remission?
Yes, some patients with metastatic cancer can achieve a partial response, complete response or a period in which no active disease is detectable. How often this occurs and how durable it is depends completely on cancer type and treatment.
For many metastatic solid tumors, long-term control is more common than permanent cure. But modern immunotherapy, targeted therapy, combination systemic treatment and aggressive local therapy in selected oligometastatic cases have created outcomes that would have been unusual in earlier eras.
A complete response should not automatically be interpreted as permanent cure. Continued surveillance remains important because microscopic disease can persist even when imaging is clear.
SUPPORTIVE & PALLIATIVE CARE
Quality of Life Is Part of Stage 4 Cancer Treatment
Serious cancer care should ask not only, “What is the scan doing?” but also, “How is the patient doing?”
Important issues can include:
- pain;
- fatigue;
- neuropathy;
- sleep;
- appetite and weight;
- nausea;
- bowel function;
- anxiety and depression;
- mobility and strength;
- treatment toxicity;
- family and caregiver burden.
ASCO recommends early palliative-care involvement for patients with advanced cancer, particularly when symptom burden or quality-of-life concerns are present.9 Palliative care can occur alongside active treatment; it is not the same as hospice.
Integrative approaches also have evidence for selected cancer-related symptoms. The joint Society for Integrative Oncology–ASCO guideline supports specific integrative interventions for cancer pain depending on the clinical context.10
SUNRIDGE MEDICAL
How Sunridge Medical Approaches Stage 4 Metastatic Cancer
At Sunridge Medical, Stage 4 cancer care is built around four questions:
1. What Is Driving the Cancer?
Primary diagnosis, pathology, metastatic pattern, molecular features, biomarkers, growth rate, previous treatment response and resistance.
2. What Is Happening in the Patient?
Blood counts, kidney and liver function, inflammation, nutrition, metabolism, symptoms, medications, sleep, activity, treatment tolerance and quality of life.
3. What Can Still Be Targeted?
Remaining standard treatments, clinical trials, biomarkers, local therapies, physician-directed integrative therapies and supportive strategies.
4. How Will We Know Whether the Plan Is Working?
Symptoms, laboratory values, tumor markers where useful, imaging, treatment tolerance, function and the overall clinical course.
We do not assume every Stage 4 patient needs the same program. A heavily pretreated metastatic pancreatic cancer patient and a newly diagnosed biomarker-positive metastatic lung cancer patient should not receive the same strategy simply because both are labeled “Stage 4.”
SCOTTSDALE • OUT-OF-STATE • INTERNATIONAL
Patients Travel to Sunridge for Stage 4 Cancer Care
Sunridge Medical is located in Scottsdale, Arizona. Patients come from Arizona, other states and internationally for individualized integrative oncology evaluation and treatment.
Before traveling, the Patient Care Team can help identify which records are most useful, including pathology, imaging reports, treatment history, recent laboratory work and molecular or biomarker testing.
BECOMING A PATIENT
What Happens When You Contact Sunridge?
- Tell us about the diagnosis. Let the Patient Care Team know the primary cancer, where it has spread, current treatment and what you are trying to explore.
- Gather the important records. Pathology, imaging, recent labs, treatment history and biomarker information are especially helpful.
- Review the case with a physician. The consultation focuses on the cancer, previous response, current options, patient health and treatment goals.
- Build the next-step strategy. When appropriate, a physician-directed integrative program can be developed around the individual case.
STAGE 4 CANCER CARE
The Bottom Line on Stage 4 Cancer Treatment
Stage 4 cancer is a serious diagnosis, but it is not a single prognosis and it is not a single treatment plan. Modern metastatic cancer care can include precision medicine, immunotherapy, targeted therapy, combination systemic treatment, metastasis-directed local treatment, clinical trials, supportive care and integrative oncology.
The most important step is to understand the individual case in enough detail to answer the right questions: What is driving the cancer? What has already failed? What has not yet been tried? What biomarkers matter? Which metastatic sites are most important? What is the patient strong enough to tolerate? What is the goal now?
For patients who want a broader Stage 4 cancer treatment review, Sunridge Medical provides physician-directed integrative oncology in Scottsdale, Arizona, with care for out-of-state and international patients.
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions About Stage 4 Cancer Treatment
Do you treat Stage 4 cancer?
Yes. Sunridge Medical evaluates patients with metastatic, recurrent and heavily treated cancers. The appropriate treatment strategy depends on the primary cancer, metastatic sites, previous therapies, current condition and available options.
Is Stage 4 cancer always terminal?
No. Stage 4 describes the extent of disease, while terminal or end-stage cancer describes a situation in which the disease can no longer be controlled. Some metastatic cancers can remain controlled for long periods.
Can I come to Sunridge while receiving chemotherapy, radiation or immunotherapy?
Yes. Many patients seek integrative care during active oncology treatment. Timing, interactions, blood counts, organ function and treatment goals should be reviewed before adding therapies.
What if chemotherapy has stopped working?
A re-review may include updated imaging, pathology, biomarker testing, unused treatment lines, targeted therapy, immunotherapy, clinical trials, local treatment of selected metastases and physician-directed integrative strategies.
What if my oncologist says there are no more standard options?
You can still request a consultation. It can be useful to clarify whether all relevant molecular testing, clinical-trial opportunities and local-treatment options have been reviewed and to discuss symptom control and integrative care.
Can Stage 4 cancer go into remission?
Some metastatic cancers can achieve partial or complete responses. The likelihood and durability of remission vary greatly by cancer type, biology and treatment.
How long can someone live with Stage 4 cancer?
There is no single answer. Some metastatic cancers progress quickly, while others can remain controlled for years. Population survival statistics cannot predict an individual patient’s course.
Do you use natural treatments for Stage 4 cancer?
Sunridge Medical may consider physician-directed natural, metabolic, botanical and intravenous therapies when they fit the patient’s diagnosis, treatment plan, organ function and clinical goals.
Do you work with my oncologist?
Many patients continue care with an outside oncologist while receiving integrative care at Sunridge. Coordination is particularly important when therapies are being used around chemotherapy, radiation, immunotherapy or targeted therapy.
Do patients travel from outside Arizona?
Yes. Sunridge Medical is in Scottsdale, Arizona, and patients travel from other states and countries for consultation and treatment.
What records should I provide?
Pathology, operative reports, imaging reports, recent laboratory work, current medications, treatment history and molecular or biomarker testing are especially useful.
PRIMARY SOURCES & GUIDELINES
References
- National Cancer Institute. Metastatic Cancer: When Cancer Spreads. Updated January 17, 2025.
- National Cancer Institute. Biomarker Testing for Cancer Treatment.
- National Cancer Institute. List of Targeted Therapy Drugs Approved for Specific Types of Cancer. Updated May 14, 2025.
- National Cancer Institute. Immune Checkpoint Inhibitors.
- National Cancer Institute. Agnostic Cancer Therapies (PDQ®). Updated 2025.
- Palma DA, et al. Stereotactic ablative radiotherapy versus standard of care in oligometastatic cancers (SABR-COMET): randomized phase II trial. Lancet. 2019.
- Palma DA, et al. Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020.
- National Cancer Institute. Choices for Cancer Care When Treatment May Not Be an Option.
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024.
- Mao JJ, et al. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline. J Clin Oncol. 2022.
- National Cancer Institute. Metastatic Cancer Research.
- Bodeker KL, et al. Randomized trial of pharmacological ascorbate with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024.
- National Cancer Institute. Intravenous Vitamin C (PDQ®), Health Professional Version.
- National Cancer Institute. Targeted Therapy for Cancer.